» Articles » PMID: 29462886

Lung Macrophage Phenotypes and Functional Responses: Role in the Pathogenesis of COPD

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2018 Feb 22
PMID 29462886
Citations 64
Authors
Affiliations
Soon will be listed here.
Abstract

Lung macrophages (LMs) are essential immune effector cells that are pivotal in both innate and adaptive immune responses to inhaled foreign matter. They either reside within the airways and lung tissues (from early life) or are derived from blood monocytes. Similar to macrophages in other organs and tissues, LMs have natural plasticity and can change phenotype and function depending largely on the microenvironment they reside in. Phenotype changes in lung tissue macrophages have been implicated in chronic inflammatory responses and disease progression of various chronic lung diseases, including Chronic Obstructive Pulmonary Disease (COPD). LMs have a wide variety of functional properties that include phagocytosis (inorganic particulate matter and organic particles, such as viruses/bacteria/fungi), the processing of phagocytosed material, and the production of signaling mediators. Functioning as janitors of the airways, they also play a key role in removing dead and dying cells, as well as cell debris (efferocytic functions). We herein review changes in LM phenotypes during chronic lung disease, focusing on COPD, as well as changes in their functional properties as a result of such shifts. Targeting molecular pathways involved in LM phenotypic shifts could potentially allow for future targeted therapeutic interventions in several diseases, such as COPD.

Citing Articles

Associations of Serum Legumain with Severity and Prognosis Among Acute Exacerbation of Chronic Obstructive Pulmonary Disease Patients.

Zhang Q, Ma M, Chen Z, Guo Y, Liu K, Xie M Int J Chron Obstruct Pulmon Dis. 2025; 20:437-447.

PMID: 40027200 PMC: 11871913. DOI: 10.2147/COPD.S507018.


Lsm2 is critical to club cell proliferation and its inhibition aggravates COPD progression.

Zhu W, Han L, He L, Peng W, Li Y, Tian W Respir Res. 2025; 26(1):71.

PMID: 40022153 PMC: 11871738. DOI: 10.1186/s12931-025-03126-8.


Advances on the Role of Lung Macrophages in the Pathogenesis of Chronic Obstructive Pulmonary Disease in the Era of Single-Cell Genomics.

Li X, Zhang H, Chi X, Ruan W, Meng X, Deng J Int J Med Sci. 2025; 22(2):298-308.

PMID: 39781522 PMC: 11704685. DOI: 10.7150/ijms.100160.


Dissecting metabolic landscape of alveolar macrophage.

Malla S, Sajeevan K, Acharya B, Chowdhury R, Saha R Sci Rep. 2024; 14(1):30383.

PMID: 39638830 PMC: 11621776. DOI: 10.1038/s41598-024-81253-w.


Ezrin drives adaptation of monocytes to the inflamed lung microenvironment.

Gudneppanavar R, Di Pietro C, H Oz H, Zhang P, Cheng E, Huang P Cell Death Dis. 2024; 15(11):864.

PMID: 39613751 PMC: 11607083. DOI: 10.1038/s41419-024-07255-8.


References
1.
Osinska I, Wolosz D, Domagala-Kulawik J . Association between M1 and M2 macrophages in bronchoalveolar lavage fluid and tobacco smoking in patients with sarcoidosis. Pol Arch Med Wewn. 2014; 124(7-8):359-64. DOI: 10.20452/pamw.2339. View

2.
Wu Y, Xu H, Li L, Yuan W, Zhang D, Huang W . Susceptibility to Aspergillus Infections in Rats with Chronic Obstructive Pulmonary Disease via Deficiency Function of Alveolar Macrophages and Impaired Activation of TLR2. Inflammation. 2016; 39(4):1310-8. PMC: 4951508. DOI: 10.1007/s10753-016-0363-x. View

3.
Aaron S, Vandemheen K, Maltais F, Field S, Sin D, Bourbeau J . TNFα antagonists for acute exacerbations of COPD: a randomised double-blind controlled trial. Thorax. 2012; 68(2):142-8. DOI: 10.1136/thoraxjnl-2012-202432. View

4.
Mammen M, Sethi S . COPD and the microbiome. Respirology. 2016; 21(4):590-9. DOI: 10.1111/resp.12732. View

5.
Walton G, Stockley J, Griffiths D, Sadhra C, Purvis T, Sapey E . Repurposing Treatments to Enhance Innate Immunity. Can Statins Improve Neutrophil Functions and Clinical Outcomes in COPD?. J Clin Med. 2016; 5(10). PMC: 5086591. DOI: 10.3390/jcm5100089. View